To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma LIMBER

What's the purpose of this trial?

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.

This trial is currently open and accepting patients.

What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

  • Agreement to avoid pregnancy or fathering children.
  • Participants who are transfusion-dependent or present with symptomatic anemia
  • For MDS participants:
    • Ineligible to receive or have not responded to available therapies for anemia such as ESAs or lenalidomide.
    • Not requiring cytoreductive therapy other than hydroxyurea.
    • BM and peripheral blood myeloblast count < 10%.
    • Histologically confirmed diagnosis of the MDS, CMML and unclassifiable MDS/MPN overlap syndromes.
  • For MM participants:
    • Histologically confirmed diagnosis of MM.
    • After failure of available standard treatments such as alkylating agents, glucocorticoids, immunomodulatory drugs (lenalidomide,pomalidomide, or thalidomide), proteasome inhibitors (bortezomib or carfilzomib), and daratumumab.

Exclusion Criteria:

  • Any prior allogeneic stem cell transplantation or a candidate for such transplantation.
  • Any major surgery within 28 days before the first dose of study drug.
  • Any prior chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, biological therapy, endocrine therapy, targeted therapy, or antibody or hypomethylating agent to treat the participant's disease within 5 half-lives or 28 days (whichever is shorter) before the first dose of study drug.
  • Undergoing treatment with another investigational medication or having been treated with an investigational medication within 28 days before the first dose of study drug. -Undergoing treatment with ESAs, granulocyte colony-stimulating factor or granulocyte/macrophage colony-stimulating factor, romiplostin, or eltrombopag at any time within 28 days before the first dose of study drug.
  • Undergoing treatment with a strong or potent inhibitor or inducer of CYP3A4/5 within 28 days or 5 half-lives (whichever is longer) before the first dose of study drug or expected to receive such treatment during the study.
  • History of clinically significant or uncontrolled cardiac disease.
  • History or presence of an abnormal ECG that, in the investigator's opinion, is clinically Meaningful.
  • Presence of chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment.
  • Diagnosis of chronic liver disease.

Additional Trial Information

Phase 1/2

Enrollment: 80 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


Stanford University Cancer Institute (Palo Alto)

Stanford, CA

Open and Accepting


Florida Cancer Specialists Sarasota Cattlemen

Sarasota, FL

Open and Accepting


Tulane Cancer Center Tulane University School of Medicine

New Orleans, LA

Open and Accepting



MD Anderson Cancer Center The University of Texas

Houston, TX

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message